​

Ionis Pharmaceuticals (IONS) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

IONS Stock Forecast

Ionis Pharmaceuticals (IONS) stock forecast, based on 32 Wall Street analysts, predicts a 12-month average price target of $87.36, with a high of $100.00 and a low of $65.00. This represents a 8.87% increase from the last price of $80.24.

$30 $44 $58 $72 $86 $100 High: $100 Avg: $87.36 Low: $65 Last Closed Price: $80.24

IONS Stock Rating

Ionis Pharmaceuticals stock's rating consensus is Buy, based on 32 Wall Street analysts. The breakdown includes 1 Strong Buy (3.12%), 19 Buy (59.38%), 12 Hold (37.50%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 32 12 19 1 Strong Sell Sell Hold Buy Strong Buy

IONS Price Target Upside V Benchmarks

TypeNameUpside
StockIonis Pharmaceuticals8.87%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts1826
Avg Price Target$100.00$95.00$80.73
Last Closing Price$80.24$80.24$80.24
Upside/Downside24.63%18.39%0.61%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 266106--22
Dec, 256116--23
Nov, 258107--25
Oct, 258107--25
Sep, 2581171-27
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 05, 2026Wells Fargo$100.00$79.6725.52%24.63%
Dec 17, 2025Luca IssiRBC Capital$95.00$78.3721.22%18.39%
Dec 15, 2025Leerink Partners$100.00$80.7223.89%24.63%
Nov 04, 2025Piper Sandler$77.00$73.854.27%-4.04%
Oct 30, 2025H.C. Wainwright$100.00$74.2434.70%24.63%
Oct 30, 2025Morgan Stanley$94.00$74.0426.96%17.15%
Oct 30, 2025Cowen & Co.$99.00$74.0033.78%23.38%
Oct 30, 2025Barclays$95.00$71.8832.16%18.39%
Oct 16, 2025Morgan Stanley$90.00$72.3924.33%12.16%
Oct 08, 2025Justin KimOppenheimer$90.00$68.9430.55%12.16%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 05, 2026Wells FargoOverweightOverweighthold
Dec 17, 2025RBC CapitalOutperformOutperformhold
Dec 03, 2025Cowen & Co.BuyBuyhold
Nov 04, 2025Piper SandlerOverweightOverweighthold
Oct 30, 2025H.C. WainwrightBuyBuyhold
Oct 30, 2025BarclaysOverweightOverweighthold
Oct 30, 2025Cowen & Co.BuyBuyhold
Oct 16, 2025Morgan StanleyOverweightOverweighthold
Oct 08, 2025OppenheimerOutperformOutperformhold
Sep 26, 2025Goldman SachsSellNeutralupgrade

Financial Forecast

EPS Forecast

$-5 $-4 $-3 $-2 $-1 $0 $1 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.21$-1.90$-2.56$-3.04----
Avg Forecast$-1.45$-2.49$-3.28$-3.48$-3.70$-2.77$-1.10$0.74
High Forecast$-1.19$-1.93$-2.81$-3.22$-2.51$-1.37$0.63$1.00
Low Forecast$-1.98$-3.17$-3.55$-3.69$-4.63$-4.44$-2.51$0.51
Surprise %-85.52%-23.69%-21.95%-12.64%----

Revenue Forecast

$0 $500M $1B $2B $2B $3B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$810.00M$587.00M$787.65M$705.14M----
Avg Forecast$650.76M$583.98M$637.10M$617.72M$670.75M$878.39M$1.26B$1.73B
High Forecast$835.45M$707.22M$677.83M$672.60M$746.22M$919.59M$1.30B$2.19B
Low Forecast$561.15M$482.28M$588.31M$595.85M$600.55M$837.19M$1.21B$1.32B
Surprise %24.47%0.52%23.63%14.15%----

Net Income Forecast

$-1B $-600M $-200M $200M $600M $1B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-29.00M$-270.00M$-366.29M$-453.90M----
Avg Forecast$390.43M$303.04M$-366.29M$-494.61M$-603.06M$-421.47M$-140.21M$105.64M
High Forecast$557.81M$471.95M$-133.57M$-461.54M$-358.99M$-196.70M$90.77M$142.72M
Low Forecast$223.04M$134.13M$-599.01M$-527.68M$-662.75M$-635.48M$-359.46M$73.45M
Surprise %-107.43%-189.10%--8.23%----

IONS Forecast FAQ

Is Ionis Pharmaceuticals stock a buy?

Ionis Pharmaceuticals stock has a consensus rating of Buy, based on 32 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 19 Buy, 12 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Ionis Pharmaceuticals is a favorable investment for most analysts.

What is Ionis Pharmaceuticals's price target?

Ionis Pharmaceuticals's price target, set by 32 Wall Street analysts, averages $87.36 over the next 12 months. The price target range spans from $65 at the low end to $100 at the high end, suggesting a potential 8.87% change from the previous closing price of $80.24.

How does Ionis Pharmaceuticals stock forecast compare to its benchmarks?

Ionis Pharmaceuticals's stock forecast shows a 8.87% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Ionis Pharmaceuticals over the past three months?

  • January 2026: 27.27% Strong Buy, 45.45% Buy, 27.27% Hold, 0% Sell, 0% Strong Sell.
  • December 2025: 26.09% Strong Buy, 47.83% Buy, 26.09% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 32.00% Strong Buy, 40.00% Buy, 28.00% Hold, 0% Sell, 0% Strong Sell.

What is Ionis Pharmaceuticals’s EPS forecast?

Ionis Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $-3.7, marking a 21.71% increase from the reported $-3.04 in 2024. Estimates for the following years are $-2.77 in 2026, $-1.1 in 2027, and $0.74 in 2028.

What is Ionis Pharmaceuticals’s revenue forecast?

Ionis Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $670.75M, reflecting a -4.88% decrease from the reported $705.14M in 2024. The forecast for 2026 is $878.39M, followed by $1.26B for 2027, and $1.73B for 2028.

What is Ionis Pharmaceuticals’s net income forecast?

Ionis Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $-603M, representing an 32.86% increase from the reported $-454M in 2024. Projections indicate $-421M in 2026, $-140M in 2027, and $105.64M in 2028.